These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18977023)

  • 1. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer.
    Muggia F
    Gynecol Oncol; 2009 Jan; 112(1):275-81. PubMed ID: 18977023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
    Saldivar JS; Wu X; Follen M; Gershenson D
    Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin and platinum drugs at the molecular level. (Review).
    Boulikas T; Vougiouka M
    Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
    Varma R; Hector S; Greco WR; Clark K; Hawthorn L; Porter C; Pendyala L
    Cancer Chemother Pharmacol; 2007 May; 59(6):711-23. PubMed ID: 17021820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular processing of platinum anticancer drugs.
    Wang D; Lippard SJ
    Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and future prospects for satraplatin, an oral platinum analogue.
    Choy H; Park C; Yao M
    Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinums: extending their therapeutic spectrum.
    Muggia FM; Fojo T
    J Chemother; 2004 Nov; 16 Suppl 4():77-82. PubMed ID: 15688617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
    Ali BH; Al Moundhri MS
    Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin for the treatment of ovarian cancer.
    Bogliolo S; Cassani C; Gardella B; Musacchi V; Babilonti L; Venturini PL; Ferrero S; Spinillo A
    Expert Opin Investig Drugs; 2015; 24(9):1275-86. PubMed ID: 26125301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the platinum analogues in bladder cancer cell lines.
    Powles T; Perry J; Shamash J; Liu W; Oliver T; Joel S
    Urol Int; 2007; 79(1):67-72. PubMed ID: 17627172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer.
    Piccart MJ; Lamb H; Vermorken JB
    Ann Oncol; 2001 Sep; 12(9):1195-203. PubMed ID: 11697824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Back to the future: Targeting molecular changes for platinum resistance reversal.
    Gabra H
    Gynecol Oncol; 2010 Sep; 118(3):210-1. PubMed ID: 20691332
    [No Abstract]   [Full Text] [Related]  

  • 13. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
    Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
    Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non platinum metal complexes as anti-cancer drugs.
    Ott I; Gust R
    Arch Pharm (Weinheim); 2007 Mar; 340(3):117-26. PubMed ID: 17315259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of the platinum analog TNO-6 in patients with advanced ovarian cancer.
    Colombo N; Sartori E; Landoni F; Favalli G; Vassena L; Zotti L; Materman E; Franks CR; Pecorelli S; Mangioni C
    Cancer Treat Rep; 1986 Jun; 70(6):793-4. PubMed ID: 3731141
    [No Abstract]   [Full Text] [Related]  

  • 18. ERCC1-immunoexpression does not predict platinum-resistance in ovarian cancer.
    Stadlmann S; Dirnhofer S; Güth U; Thies S; Singer G
    Gynecol Oncol; 2008 Jan; 108(1):252-3. PubMed ID: 17936339
    [No Abstract]   [Full Text] [Related]  

  • 19. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
    Zhang Y; Wang J; Xiang D; Wang D; Xin X
    Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.